Meropenem pharmacokinetics in a patient with multiorgan failure from Meningococcemia undergoing continuous venovenous hemodiafiltration.
Meropenem is a carbapenem antibiotic with a broad antibacterial spectrum of activity. Its main route of elimination is through the kidneys, with 63% of the drug excreted unchanged in the urine. Meropenem clearance is diminished in renal impairment; therefore, doses need to be adjusted in patients with varying degrees of renal function. An appropriate dose of meropenem for patients undergoing continuous venovenous hemodiafiltration (CVVHDF) is unknown. We evaluated the pharmacokinetics of meropenem in a patient with fulminant meningococcemia undergoing CVVHDF. Meropenem concentrations in serial venous, arterial, and ultrafiltrate samples after a 1 g intravenous dose were measured using high-performance liquid chromatography (HPLC). Meropenem clearance was found to be 129.36 mL/min and 141.29 mL/min for every 8- and 12-hour dosing, respectively. Trough levels were above the MIC90 for Neisseria meningitidis and most anaerobic pathogens. We recommend that meropenem 1 g intravenously every 12 hours be used as the initial dose in patients undergoing CVVHDF. Differences between meropenem clearance during CVVHDF and other forms of renal replacement therapy are discussed.
Meyer
M M
MM
Department of Medicine, Oregon Health Sciences University, Portland, OR, USA.
Munar
M Y
MY
Kohlhepp
S J
SJ
Bryant
R E
RE
D000328:Adult; D016470:Bacteremia / Q000150:complications / Q000628:therapy*; D015780:Carbapenems / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D017583:Hemodiafiltration; D006801:Humans; D008297:Male; D008589:Meningococcal Infections / Q000150:complications / Q000628:therapy*; D000077731:Meropenem; D009102:Multiple Organ Failure / Q000378:metabolism*; D013845:Thienamycins / Q000493:pharmacokinetics*
D015780:Carbapenems; D013845:Thienamycins; D000077731:Meropenem